Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Furness in new CDER role; Oxytrol for Women at retail; advisories on drug-tainted sex enhancers; senators want energy drink restrictions

This article was originally published in The Tan Sheet

Executive Summary

Furness takes on new CDER role; Merck’s Oxytrol OTC arrives at retail; FDA issues advisory on drug-tainted sex enhancers; senators want energy drink restrictions; more news In Brief.

You may also be interested in...



DMAA Product OxyElite Pro Named Potential Link In Acute Hepatitis Cases

FDA is investigating 29 reports of acute non-viral hepatitis in Hawaii, and the state Department of Health says 24 cases share a common link to the use of products labeled as USPlabs’ DMAA product, OxyElite Pro.

DMAA Product OxyElite Pro Named Potential Link In Acute Hepatitis Cases

FDA is investigating 29 reports of acute non-viral hepatitis in Hawaii, and the state Department of Health says 24 cases share a common link to the use of products labeled as USPlabs’ DMAA product, OxyElite Pro.

Firms Explore First-In-Class Switches With NSURE Still In Limbo

Firms are moving forward with potential first-in-class switches for chronic conditions, says Concentrics Research CEO Julie Aker. Meanwhile, FDA’s NSURE initiative offers “a lot of opportunity,” but “is still very conceptual,” the agency says.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS106634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel